Genetic tests - overview of the situation in the light of the technological developments:An example of the Czech Republic
Abstract
The main aim of the presentation was to provide an overview on the increasing disparities in terms of the rapid production of biomedical data, by e.g. next generation sequencing technologies (NGS) in genetics/genomics, and lagging clinical validity and utility of such data within the domain of health care. The falling price of DNA sequencing which now exceeds Moore's law for semiconductors and the relative rapid increase in genetic testing outside of the traditional "germ line" genome domain i.e. testing of somatic mutations in oncology, minimal residual disease in hematooncology, microbiology, creates strong pressures on finite resources in all solidarity principle based European health care systems.
Moreover, some low-resourced countries are in the risk that they will be completely left out of the "omics" biomedical revolution and are increasingly lagging behind with relevant health care applications.